MP28-07 THE ASSOCIATION OF SOLUBLE PD-L1 AND TREATMENT RESPONSE TO NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP28-07 THE ASSOCIATION OF SOLUBLE PD-L1 AND TREATMENT RESPONSE TO NIVOLUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Naoto Wakita, Yukari Bando, Junya Furukawa, Nobuyuki Hinata, Yuzo Nakano, and Masato Fujisawa Naoto WakitaNaoto Wakita More articles by this author , Yukari BandoYukari Bando More articles by this author , Junya FurukawaJunya Furukawa More articles by this author , Nobuyuki HinataNobuyuki Hinata More articles by this author , Yuzo NakanoYuzo Nakano More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003256.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Effective treatment options for metastatic renal cell carcinoma (mRCC) have been increasing. Therefore, predictors of treatment response are important. PD-L1 expression in renal cancer has been reported as a predictor of treatment response and prognosis. However, PD-L1 expression by immunohistochemistry is invasive and difficult to assess repeatedly. Recently, it has been shown that soluble PD-L1 (sPD-L1) is useful as a predictor in several tumors. Therefore, we evaluated sPD-L1 in mRCC patients treated with nivolumab and investigated the association between sPD-L1 and treatment response. METHODS: This study was a prospective single-arm study. Patients with mRCC treated with nivolumab as second line or later were included. We measured serum sPD-L1 in patients before and during treatment. The patients were classified based on baseline sPD-L1 (sPDL1 ≥0.23 ng/ml vs <0.23 ng/ml). We compared outcomes between the two groups. RESULTS: A total of 43 patients with mRCC were included in this study, with 17 (39.5%) low sPD-L1 patients and 26 (60.5%) high sPD-L1 patients. The International Metastatic RCC Database Consortium risk score was significantly poorer in the high sPD-L1 group. The objective response rate was significantly higher (41.2% vs 7.7%) and overall survival significantly longer (p=0.03) in the low group compared with the high group. There were no significant differences in progression-free survival between the two groups. CONCLUSIONS: The present study indicated that sPD-L1 might be a predictor of treatment response to nivolumab for mRCC patients. Source of Funding: This work was supported by Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb, Co © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e372 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Naoto Wakita More articles by this author Yukari Bando More articles by this author Junya Furukawa More articles by this author Nobuyuki Hinata More articles by this author Yuzo Nakano More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement PDF downloadLoading ...